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Abstract
Brachyury is a marker for notochord-derived tissues and neoplasms, such as chordoma. However, the prognostic
relevance of brachyury expression in chordoma is still unknown. The improvement of tissue microarray technology
has provided the opportunity to perform analyses of tumor tissues on a large scale in a uniform and consistent
manner. This study was designed with the use of tissue microarray to determine the expression of brachyury.
Brachyury expression in chordoma tissues from 78 chordoma patients was analyzed by immunohistochemical
staining of tissue microarray. The clinicopathologic parameters, including gender, age, location of tumor and
metastatic status were evaluated. Fifty-nine of 78 (75.64%) tumors showed nuclear staining for brachyury, and
among them, 29 tumors (49.15%) showed 1+ (<30% positive cells) staining, 15 tumors (25.42%) had 2+ (31% to
60% positive cells) staining, and 15 tumors (25.42%) demonstrated 3+ (61% to 100% positive cells) staining.
Brachyury nuclear staining was detected more frequently in sacral chordomas than in chordomas of the mobile spine.
However, there was no significant relationship between brachyury expression and other clinical variables. By Kaplan-
Meier analysis, brachyury expression failed to produce any significant relationship with the overall survival rate. In
conclusion, brachyury expression is not a prognostic indicator in chordoma.
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Introduction
Chordoma is a rare malignant bone tumor but is the most
common primary malignant tumor of the mobile spine and the
sacrum [1,2]. Chordoma is slow growing and is often detected
only after substantial growth [2,3]. Due to location, they are
difficult to treat and have a high local recurrence rate;
furthermore, no biomarkers are available to predict their clinical
behavior.
Chordoma is thought to be derived from notochordal
remnants or so called benign notochordal cell tumors (BNCT)
[2,3]. However, the carcinogenesis and pathogenesis for
development of chordoma remains largely unclear, although
studies have showed that the gain of brachyury locus is
common in chordomas, and expression of this gene might play
a crucial role in the pathogenesis of chordoma [4-7]. Brachyury
(also known as transcription factor T) is a member of the T-box
family, expressed commonly in notochord cells and plays a
pivotal role in notochord development and formation [8].
Expression of brachyury is regulated by the Wnt signaling
pathway which in turn is mediated by the β-catenin/TCF4
complex in the development of mesoderm tissues in mouse
[9,10]; however, active WNT signalling has not been
established in chordoma. Brachyury is also significantly
expressed in the majority of chordoma tissues in comparison to
other types of cancer and thought to be a novel biomarker for
chordoma [4,6,11]. High-resolution array comparative genomic
hybridization (CGH) shows unique duplications in the 6q27
region in tumor samples from patients with familial chordoma
[5]. In sporadic chordoma, a study of 21 tumors analyzed by
CGH showed large copy number losses, involving
chromosomes 1p, 3, 4, 9, 10, 13, 14, and 18, were more
common than copy number gains. Most of these sporadic
tumors are not associated with brachyury duplication or
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amplification [12]. In comparison, another study noticed that
copy number gain (CNG) of brachyury gene was found in 92
out of 170 chordoma patients by fluorescence in situ
hybridization (FISH) [13]. However, the association between
the protein level of brachyury expression and clinical behavior
in chordoma is still unknown.
The tissue microarray (TMA) is a recently implemented, high-
throughput technology used in the analysis of molecular
markers in oncology. As compared with conventional
immunohistochemistry, TMAs allow for a large scale study of
tumor tissue samples in a uniform and consistent manner
[14-16]. . For this study we designed a chordoma TMA which
included tumor tissues from 78 patients to correlate the
expression of brachyury with clinical outcome.
Materials and Methods
Ethic Statement
The study protocol and the consent of the informed patients
were approved by the Partners Human Research Committee
(number: 2007-P-002464/5 valid until 10/19/2013). All patients
were informed of their information being
stored in the hospital database and used for research and have
given their written approval.
Patient’s Clinical Data and Specimens
A retrospective study of 78 chordoma patients was identified
for TMA immunohistochemical staining by using the
Massachusetts General Hospital cancer registry and
orthopedic oncology databases. The data of each patient’ age,
gender, date of birth, tumor location(s), date of death (if
applicable), and disease status were collected. Those patients
with archival tissue blocks available through the Department of
Pathology were selected. The hematoxylin-eosin (H&E) stained
slides of the paraffin-embedded tumor specimens were
reviewed by one of the authors (GPN). In this study, we only
inculded chordomas with a conventional morphology, whereas
dedifferentiated and chondroid chordoma subtypes were
excluded. The clinical data of chordoma patients were
presented in the Table 1.
Construction of the Chordoma TMA
Representative areas of chordoma tumor slides of the
paraffin-embedded tumor specimens for each case were
selected and circled to match the blocks for the TMA. The
blocks matching the circled slides were retrieved to prepare the
recipient block for the microarray. To ensure accurate
representation of the selected cores, three areas of tumor parts
per case were selected for assembling the recipient master
blocks. Each target area on the selected blocks was punched
to form a 0.5 mm diameter tissue core and was placed
consecutively on the recipient master blocks. The chordoma
TMA was constructed by the Tissue Microarray and Imaging
Core at the Dana-Farber/Harvard Cancer Center (http://
genepath.med.harvard.edu:8080/pathcore/).
Immunohistochemical Staining and Analysis
A tissue microarray of chordoma was used for this
retrospective analysis, including 291 cores from 97 specimens
(78 chordoma cancers, 6 notochord controls, 2 chordoma cell
lines (UCH1 and CH 8) [17] and 11 tissue controls including 7
normal tissues near the chordoma, 4 other malignant tumors
(each of breast, kidney, melanoma and liver cancer)
Immunohistochemical stain with goat antibody (sc-17745)
against human Brachyury (Santa Cruz Biotechnology, Inc., CA,
USA) was performed by using Cell and Tissue Staining Kit
(Goat kit, R&D Systems, Inc., Minneapolis, MN, USA). Briefly,
5-µm-thick array sections were baked at 60°C for 1h, dewaxed
with xylene (triple for 5 minutes), transferred through 100%
ethanol (twice for 5 minutes), rehydrated through graded
alcohol, and then immersed in deionized water for 10 minutes.
Antigen retrieval was processed with Target Retrieval Solution
(Dako, North America, Inc., CA, USA) following the instruction
of the manufacturer. In brief after antigen retrieval, the slide
was washed with PBS twice for 5 minutes. Endogenous avidin/
biotin binding was blocked according to the instruction of
staining kit. Primary goat brachyury antibody was applied at 4
°C overnight (1:100 dilution, in 1% bovine serum albumin PBS).
After incubation with the biotinylated anti-goat antibody, and
then with HSS-HRP, the slide was rinsed in PBS thrice, bound
antibody was detected with the substrate reagents from HRP-
DAB system of Cell and Tissue Staining Kit. Finally, sections
were counterstained with Hematoxylin QS (Vector
Table 1. The clinical parameters of chordoma tissue
microarray.
Parameters n(%)
Age  46
 <45 8 (17.40)
 45-60 16 (34.78)
 >60 22 (47.83)
Gender  74
 Male 56 (75.67)
 Female 18 (4.32)
Location  63
 Mobilespine 21 (33.33)
 Sacrum 42 (66.67)
Prognosis  61
 Survival 27 (44.26)
 Nonsurvival 34 (55.73)
Disease status  78
 Primary 29 (37.17)
 Recurrence 41 (52.56)
 Metastasis 8 (10.25)
Disease status  78
 NED 27 (44.26)
 AWD 7 (11.47)
 DOD 23 (37.7)
 Dead with other disease 4 (6.55)
doi: 10.1371/journal.pone.0075851.t001
Brachyury in Chordoma
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Laboratories) and the slide was mounted with VectaMount AQ
(Vector Laboratories).
Brachyury-positive samples were defined as those showing
nuclear staining. Brachyury staining patterns were categorized
into 4 groups: 0, no nuclear staining; 1+, <=30% staining of
tumor cells; 2+, 31% to 60% staining of tumor cells; 3+, 61% to
100% staining of tumor cells. The percentage of cells showing
positive nuclear staining for brachyury was calculated by
reviewing the entire spot. Categorizing the brachyury staining
was completed by 2 independent investigators in the Sarcoma
Research Laboratory, who were blinded to the clinicopathologic
data, with a consensus reached in all cases. Brachyury staining
images were obtained by using a Nikon Eclipse Ti-U
fluorescence microscope (Nikon Corp) with a SPORT RT
digital camera (Diagnostic Instruments Inc.).
Statistical Analyses
A two-sided Student’s t-test (GraphPad PRISM Software;
GrahPad Software, Inc., CA, USA) was used to compare the
differences between groups, including male vs. female, survival
vs. non-survival, and mobile spine vs. sacrum. Analyses were
also performed by comparing the relationship between the
expression of brachyury and age, metastasis of tumor and
other disease status. Results are given as mean + SD and
values with P < 0.05 were considered as statistically significant.
Kaplan–Meier survival analysis was used to analyze the
correlation between the level of brachyury expression and
prognosis. Survival time was calculated from the date of tumor
diagnosis to the date of death or last follow-up.
Results
Expression of Brachyury in Chordoma
Brachyury nuclear staining was detected in 59 (75.64%) of
78 tumors. Nineteen (24.35%) of 78 tumors were negative for
brachyury staining (Figure 1a). Among the positive tumors, 29
(49.15%) showed 1+ (<=30% of positive nuclear staining cells)
staining (Figure 1b), 15 tumors (25.42%) had 2+ (31% to 60%
of positive nuclear staining cells) staining (Figure 1c), and 15
tumors (25.42%) demonstrated 3+ (61% to 100% of positive
nuclear staining cells) staining (Figure 1d).
In addition, 6 notochord controls and 4 other malignant
tumors, breast, kidney, melanoma and liver cancer were
positive for brachyury nuclear staining. One of 2 chordoma cell
lines (UCH1) also stained positive for brachyury. Normal liver
tissue did not demonstrate nuclear expression of brachyury.
Association of Brachyury Expression and Clinical Data
Based on the location of chordoma, we grouped the
chordomas into two groups, those arising in the mobile spine
and those arising in the sacrum. There was a significant
difference in the expression of brachyury between tumors of
the mobile spine and those arising in the sacrum (P=0.027)
(Table 2); brachyury nuclear staining was detected more
frequently in sacral chordomas than in mobile spine
chordomas. Chordoma patients were also divided into 2 groups
based on gender and 3 groups based on their age (less or
equal than 45 years old group, 46 to 60 years old group and
over 60 years old group). Immunohistochemical staining
showed that expression of brachyury was not associated with
gender or age (Table 2). With respect to the relationship
between expression of brachyury and disease status,
brachyury nuclear staining was present in 23 of 29 (79.31%)
primary chordomas, 31 of 41 (75.60%) recurrent chordomas
and 5 of 8 (62.5%) metastatic chordomas. No significant
difference of brachyury expression was detected between
primary and recurrent chordoma (P=0.69), or primary and
metastatic chordoma (P=0.37) (Table 2).
Expression of Brachyury and Prognosis
Follow-up data were available for 61 of 78 (78.20%) patients.
The median follow-up period was 68.70 (range from 3.63 to
249.63) months. At the date of last follow-up, 27 patients had
died of disease (DOD), 7 patients were alive with disease
(AWD), 23 patients had no evidence of disease (NED) and 4
patients had died of other causes. No significant difference in
brachyury expression was identified between these groups of
patients (data not shown). By Kaplan-Meier survival analysis,
brachyury expression failed to have any significant relationship
with the overall survival rate for chordoma patients (Figure 2).
There was no significant difference between survival and non-
survival groups (P=0.8479, Table 2).
Dissusion
New technological developments such as TMAs are
extremely useful for the study of a large cohort of tumor
samples. TMA is an effective tool, particularly in translational
research and clinical trials, allowing resource-efficient use, and
high-throughput profiling of large numbers of tumors, although
a concern has been raised about the representation of tumor
tissues on the TMA to the whole tumor [14,15]. However, this
potential problem can be overcome by accurately evaluating
the original tumor tissues collected from a highly representative
area, together with the inclusion of three cores in assembling
the TMA. In addition, the evaluation of a large cohort of tumor
Figure 1.  Representative expression of brachyury in
chordoma tissues on TMA slide.  a 0 staining, no nuclear
staining of tumor cells; b 1+ staining, <=30% nuclear staining of
tumor cells, c 2+ staining 31% to 60% positive nuclear staining;
and d 3+ staining, 61% to 100% nuclear staining.
doi: 10.1371/journal.pone.0075851.g001
Brachyury in Chordoma
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samples in a single slide is very valuable, especially in an
extremely rare tumor such as chordoma in which approximately
300 cases are diagnosed each year in the United States (http://
www.chordomafoundation.org). Therefore, we constructed a
chordoma TMA with 78 tumor samples, 6 notochord controls, 2
chordoma cell lines and 11 tissues controls including 7 normal
tissues adjacent to the chordoma and 4 other malignant
tumors.
Table 2. Brachyury immunohistochemical staining scores in
different groups of chordomas.
 0 1+ 2+ 3+ P value
Gender      
Male 13 22 11 10 0.69
Female 4 6 4 4  
Location      
Mobilespine 9 7 2 3 0.03
Sacrum 6 16 10 10  
Prognosis      
Survival 6 10 6 5 0.84
Nonsurvival 9 12 6 7  
Age      
subgroup 1: <45 3 3 1 1 0.41*
subgroup 2: 45-60 4 4 6 2 0.80#
subgroup 3: >60 4 9 3 6 0.28&
Disease status      
subgroup 1: Primary 6 12 3 8 0.69*
subgroup 2: Recurrence 10 15 9 7 0.50#
subgroup 3: Metastasis 3 2 3 0 0.37&
*. indicates the P value of subgroup 1 v.s. subgroup 2
#. indicates the P value of subgroup 2 v.s. subgroup 3
&. indicates the P value of subgroup 1 v.s. subgroup 3
doi: 10.1371/journal.pone.0075851.t002
Figure 2.  Analyses of association between expression of
brachyury and survival for chordoma.  Kaplan-Meier
survival analysis showed that the expression of brachyury was
not associated with prognosis in patients with chordoma.
doi: 10.1371/journal.pone.0075851.g002
Recent reports suggest that brachyury might be essential for
the survival or proliferation of tumor cells [4,6]. Brachyury is a
gene of emerging significance in cancer; it is duplicated in
individuals with familial chordoma and it is amplified in around
7% of sporadic chordomas, and silencing of the gene in vitro by
siRNA induces growth arrest of chordoma cells [6]. The results
of immunohistochemical examinations of brachyury are
controversial. Several studies have shown that brachyury is not
expressed in non-chordoma tumors but recent studies have
shown that brachyury is expressed in many other types of
tumors, including hemangioblastoma, breast, bladder, kidney,
ovary, prostate, colon and lung cancers [4,18-20]. Reports
have shown that brachyury is expressed in 41% of primary lung
carcinomas, including 48% of adenocarcinomas and 25% of
squamous cell carcinomas [18,19]. A more recent study found
in vivo treatment of tumor xenografts of human lung carcinoma
cells with chemotherapy results in the selective growth of
resistant tumors with high levels of brachyury protein
expression [21]. Therefore, targeting brachyury may offer new
therapeutic options for treating various cancers, including
chordoma [22]. In order to characterize the relationship
between the protein level of brachyury expression and clinical
behavior, we used a chordoma TMA that allowed the
simultaneous characterization of the expression status of
brachyury in 78 chordoma samples. Our study showed that 59
of 78 (75.64%) tumors had positive brachyury nuclear staining.
Among them, 29 tumors (49.15%) had 1+ (<=30% of positive
nuclear staining cells) staining, 15 tumors (25.42%) had 2+
(31% to 60% of positive nuclear staining cells) staining, and 15
tumors (25.42%) showed 3+ (61% to 100% of positive nuclear
staining cells) staining. In comparison, previous studies have
shown brachyury expression in 80 to 90% of chordoma
[4,23,24]. This discrepancy between reported results and our
TMA staining are most likely due to differences in the relative
sensitivities of the methods used such as different antigen
retrieval procedure, or heterogeneity of the material analyzed.
Moreover, the immunohistochemical staining of chordoma in
most previous studies is based on multiple slides, rarely on a
single TMA slide.
Statistical analysis showed that brachyury nuclear staining
was detected more frequently in sacral chordoma than in
mobile spine chordoma. The reason for brachyury positive
staining in sacral chorndoma is higher than middle spine is
unknown, but may reflect the location of notochord remanants,
the main embryonic axial structure, which is thought to be the
origin of where chordoma is derived.
It has been reported that early stages colorectal cancer
patients showed decreased survival when brachyury was
expressed in the tumor tissue, while no correlation was
observed in patients with later tumor stages [25]. In the current
study, brachyury expression failed to exhibit a significant
relationship with the overall survival rate for chordoma patients.
There was no significant relationship between brachyury
expression and other clinical variables.
In conclusion, this study showed brachyury expression is not
associated with the clinical behavior in chordoma. Further
studies of a larger sample size and additionally chordoma
biomarkers that could predict clinical outcome are needed.
Brachyury in Chordoma
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